Professional
Added to YB: 2024-12-13
Pitch date: 2024-10-20
LQDA [bullish]
Liquidia Corporation
+235.56%
current return
Author Info
No bio for this author
Company Info
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.
Market Cap
$3.0B
Pitch Price
$11.22
Price Target
30.00 (-20%)
Dividend
N/A
EV/EBITDA
-61.70
P/E
-42.93
EV/Sales
18.94
Sector
Pharmaceuticals
Category
special_situation
Arquitos Capital Management Portfolio Holding: Liquidia Corporation
LQDA: FDA delays Yutrepia launch to May 2025, but superior product expected to capture 50%+ PAH/PH-ILD market share. Potential for earlier approval or buyout. $19-$30 price targets from analysts. Current price $11.14. CEO projects 80-90% market share. Patience likely rewarded despite setbacks.
Read full article (3 min)